儿童急性白血病经αβ T细胞与B细胞去除后行单倍体相合造血干细胞移植的结局
这项前瞻性试验评估80例急性白血病儿童在经αβ T细胞和B细胞去除的单倍体相合移植后的结局,移植时间为2011年9月至2014年9月。中位随访46个月,5年无慢性GVHD无复发生存率为71%,非复发死亡累积发生率5%,复发累积发生率24%。含全身照射的预处理方案是唯一有利影响复发和GRFS的变量。
要点
- 80例急性白血病儿童接受αβ T细胞和B细胞去除的单倍体相合移植,5年GRFS为71%。
- 仅30%发生1-2级皮肤急性GVHD,无广泛性慢性GVHD,非复发死亡累积发生率5%。
- 含全身照射的预处理方案是唯一有利影响复发发生率和GRFS的变量。
核心结论
- 经αβ T细胞和B细胞去除后的单倍体相合造血干细胞移植是急需异基因移植的急性白血病儿童的一种有竞争力的替代选择。
研究设计与样本
- 前瞻性试验纳入80例于2011年9月至2014年9月期间移植的急性白血病儿童,均接受完全清髓性预处理方案。
- 移植物经αβ T细胞和B细胞阴性去除,从-5天至-3天使用抗T淋巴细胞球蛋白预防移植物排斥和GVHD,无患者接受移植后GVHD预防。
主要发现
- 2例发生原发性植入失败;仅皮肤1-2级急性GVHD累积发生率为30%;无患者发生广泛性慢性GVHD。
- 4例死亡,非复发死亡累积发生率为5%;19例复发,复发累积发生率为24%。
- 存活患者中位随访46个月,5年无慢性GVHD无复发生存(GRFS)概率为71%。
- 含全身照射的预处理方案是唯一有利影响复发发生率和GRFS的变量。
- 这80例患者的结局与同期41例接受HLA相合同胞移植和51例接受10/10等位基因相合无关供者移植的儿童相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic stem cell transplantation (HSCT) from an HLA-haploidentical relative (haplo-HSCT) is a suitable option for children with acute leukemia (AL) either relapsed or at high-risk of treatment failure. We developed a novel method of graft manipulation based on negative depletion of αβ T and B cells and conducted a prospective trial evaluating the outcome of children with AL transplanted with this approach. Eighty AL children, transplanted between September 2011 and September 2014, were enrolled in the trial. All children were given a fully myeloablative preparative regimen. Anti-T-lymphocyte globulin from day -5 to -3 was used for preventing graft rejection and graft-versus-host disease (GVHD); no patient received any posttransplantation GVHD prophylaxis. Two children experienced primary graft failure. The cumulative incidence of skin-only, grade 1-2 acute GVHD was 30%; no patient developed extensive chronic GVHD. Four patients died, the cumulative incidence of nonrelapse mortality being 5%, whereas 19 relapsed, resulting in a 24% cumulative incidence of relapse. With a median follow-up of 46 months for surviving patients, the 5-year probability of chronic GVHD-free, relapse-free survival (GRFS) is 71%. Total body irradiation-containing preparative regimen was the only variable favorably influencing relapse incidence and GRFS. The outcomes of these 80 patients are comparable to those of 41 and 51 children given transplantation from an HLA-identical sibling or a 10/10 allelic-matched unrelated donor in the same period. These data indicate that haplo-HSCT after αβ T- and B-cell depletion represents a competitive alternative for children with AL in need of urgent allograft. This trial was registered at www.clinicaltrials.gov as #NCT01810120.
引用
- Locatelli F, Merli P, Pagliara D, et al. Outcome of children with acute leukemia given HLA-haploidentical HSCT after αβ T-cell and B-cell depletion. Blood. 2017. PMID: 28588018. doi:10.1182/blood-2017-04-779769
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。